Stock Market News

GlenmarkPharma gains 4% on USFDA approval for anti-anginal drug.

Glenmark Pharmaceuticals shares rallied 3.6 percent intraday on July 9 after the company received approval from US health regulator for anti-anginal drug.

The US Food and Drug Administration granted its approval for Ranolazine extended-release tablets, which will be available in 500 mg and 1,000 mg strengths.

Ranolazine is a generic version of Ranexa extended-release tablets of Gilead Sciences, Inc. The drug improves blood flow to help the heart work more efficiently.

For Real Time News & Trading Trends Keep Liking Epic Research Limited

Facebook

Twitter

YouTube

Pinterest

Linkedin

Google+

Share Button
Epic Research
Epic Research
Epic Research - Investment Adviser is a leading financial services provider with presence in Indian and other global capital markets. Call on - 0731-664-2300
https://www.epicresearch.co/